These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 8109837

  • 1. Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition.
    Flanagan WM, Crabtree GR.
    Ann N Y Acad Sci; 1993 Nov 30; 696():31-7. PubMed ID: 8109837
    [Abstract] [Full Text] [Related]

  • 2. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes.
    Morice WG, Brunn GJ, Wiederrecht G, Siekierka JJ, Abraham RT.
    J Biol Chem; 1993 Feb 15; 268(5):3734-8. PubMed ID: 8429048
    [Abstract] [Full Text] [Related]

  • 3. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.
    Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT.
    J Biol Chem; 1993 Oct 25; 268(30):22737-45. PubMed ID: 8226784
    [Abstract] [Full Text] [Related]

  • 4. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle.
    Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW.
    J Cell Physiol; 1993 Jan 25; 154(1):7-15. PubMed ID: 8419408
    [Abstract] [Full Text] [Related]

  • 5. Sanglifehrin A, a novel cyclophilin-binding immunosuppressant, inhibits IL-2-dependent T cell proliferation at the G1 phase of the cell cycle.
    Zhang LH, Liu JO.
    J Immunol; 2001 May 01; 166(9):5611-8. PubMed ID: 11313401
    [Abstract] [Full Text] [Related]

  • 6. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.
    Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR.
    Nature; 1992 Jul 02; 358(6381):70-3. PubMed ID: 1614535
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin.
    Aagaard-Tillery KM, Jelinek DF.
    Cell Immunol; 1994 Jul 02; 156(2):493-507. PubMed ID: 7517796
    [Abstract] [Full Text] [Related]

  • 8. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line.
    Jayaraman T, Marks AR.
    J Biol Chem; 1993 Dec 05; 268(34):25385-8. PubMed ID: 7503980
    [Abstract] [Full Text] [Related]

  • 9. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.
    Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM.
    Nature; 1994 Dec 08; 372(6506):570-3. PubMed ID: 7990932
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells.
    Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT.
    Prog Cell Cycle Res; 1995 Dec 08; 1():53-71. PubMed ID: 9552353
    [Abstract] [Full Text] [Related]

  • 11. Cell cycle progression out of G1 sensitizes primary-cultured nontransformed T cells to TCR-mediated apoptosis.
    Radvanyi LG, Shi Y, Mills GB, Miller RG.
    Cell Immunol; 1996 Jun 15; 170(2):260-73. PubMed ID: 8660826
    [Abstract] [Full Text] [Related]

  • 12. Effect of rapamycin on the expression of the IL-2 receptor (CD25).
    Woerly G, Brooks N, Ryffel B.
    Clin Exp Immunol; 1996 Feb 15; 103(2):322-7. PubMed ID: 8565319
    [Abstract] [Full Text] [Related]

  • 13. Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells.
    Javier AF, Bata-Csorgo Z, Ellis CN, Kang S, Voorhees JJ, Cooper KD.
    J Clin Invest; 1997 May 01; 99(9):2094-9. PubMed ID: 9151781
    [Abstract] [Full Text] [Related]

  • 14. Regulation of cAMP-responsive enhancer binding proteins during cell cycle progression in T lymphocytes stimulated by IL-2.
    Feuerstein N, Huang D, Hinrichs SH, Orten DJ, Aiyar N, Prystowsky MB.
    J Immunol; 1995 Jan 01; 154(1):68-79. PubMed ID: 7995960
    [Abstract] [Full Text] [Related]

  • 15. Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte. Evidence for inhibition of CREB/ATF binding activities.
    Feuerstein N, Huang D, Prystowsky MB.
    J Biol Chem; 1995 Apr 21; 270(16):9454-8. PubMed ID: 7721872
    [Abstract] [Full Text] [Related]

  • 16. HTLV-I-induced T-cell activation.
    Buckle GJ, Hafler DA, Höllsberg P.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr 21; 13 Suppl 1():S107-13. PubMed ID: 8797712
    [Abstract] [Full Text] [Related]

  • 17. The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines.
    Hultsch T, Martin R, Hohman RJ.
    Mol Biol Cell; 1992 Sep 21; 3(9):981-7. PubMed ID: 1384815
    [Abstract] [Full Text] [Related]

  • 18. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.
    Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Abraham RT.
    EMBO J; 1996 Oct 01; 15(19):5256-67. PubMed ID: 8895571
    [Abstract] [Full Text] [Related]

  • 19. IL-2-dependent induction of G1 cyclins in primary T cells is not blocked by rapamycin or cyclosporin A.
    Turner JM.
    Int Immunol; 1993 Oct 01; 5(10):1199-209. PubMed ID: 8268127
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation.
    Powell JD, Lerner CG, Schwartz RH.
    J Immunol; 1999 Mar 01; 162(5):2775-84. PubMed ID: 10072524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.